Cargando…
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
DDX60, an interferon (IFN)-inducible gene, plays a promotional role in many tumors. However, its function in glioma remains unknown. In this study, bioinformatic analysis (TCGA, CGGA, Rembrandt) illustrated the upregulation and prognostic value of DDX60 in gliomas. Immunohistochemical staining of cl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222729/ https://www.ncbi.nlm.nih.gov/pubmed/34178649 http://dx.doi.org/10.3389/fonc.2021.665360 |
_version_ | 1783711547836596224 |
---|---|
author | Zhang, Jingwen Fu, Minjie Zhang, Mengli Zhang, Jinsen Du, Zunguo Zhang, Hongyi Hua, Wei Mao, Ying |
author_facet | Zhang, Jingwen Fu, Minjie Zhang, Mengli Zhang, Jinsen Du, Zunguo Zhang, Hongyi Hua, Wei Mao, Ying |
author_sort | Zhang, Jingwen |
collection | PubMed |
description | DDX60, an interferon (IFN)-inducible gene, plays a promotional role in many tumors. However, its function in glioma remains unknown. In this study, bioinformatic analysis (TCGA, CGGA, Rembrandt) illustrated the upregulation and prognostic value of DDX60 in gliomas. Immunohistochemical staining of clinical samples (n = 49) validated the DDX60 expression is higher in gliomas than in normal tissue (n = 20, P < 0.0001). It also could be included in nomogram as a parameter to predict the 3- and 5-year survival risk (C-index = 0.86). The biological process of DDX60 in glioma was mainly enriched in the inflammatory and immune response by GSEA and GO analysis. DDX60 expression had a positive association with most inflammatory-related functions, such as hematopoietic cell kinase (HCK) (R = 0.31), interferon (R = 0.72), STAT1 (R = 54), and a negative correlation with IgG (R = −0.24). Furthermore, DDX60 expression tends to be positively related to multiple infiltrating immune cells, while negatively related to CD56 dim nature killer cell in glioma. Some important immune checkpoints, like CTLA-4, PD-L1, EGF, CD96, and CD226, were all positively related with DDX60 (all Pearson correlation R > 0.26). The expression and correlation between DDX60, EGF, and PD-L1 were confirmed by western blot in clinical samples (n = 14, P < 0.0001) and GBM cells. These results indicated that DDX60 might have important clinical significance in glioma and could serve as a potential immune therapeutic target. |
format | Online Article Text |
id | pubmed-8222729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82227292021-06-25 DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker Zhang, Jingwen Fu, Minjie Zhang, Mengli Zhang, Jinsen Du, Zunguo Zhang, Hongyi Hua, Wei Mao, Ying Front Oncol Oncology DDX60, an interferon (IFN)-inducible gene, plays a promotional role in many tumors. However, its function in glioma remains unknown. In this study, bioinformatic analysis (TCGA, CGGA, Rembrandt) illustrated the upregulation and prognostic value of DDX60 in gliomas. Immunohistochemical staining of clinical samples (n = 49) validated the DDX60 expression is higher in gliomas than in normal tissue (n = 20, P < 0.0001). It also could be included in nomogram as a parameter to predict the 3- and 5-year survival risk (C-index = 0.86). The biological process of DDX60 in glioma was mainly enriched in the inflammatory and immune response by GSEA and GO analysis. DDX60 expression had a positive association with most inflammatory-related functions, such as hematopoietic cell kinase (HCK) (R = 0.31), interferon (R = 0.72), STAT1 (R = 54), and a negative correlation with IgG (R = −0.24). Furthermore, DDX60 expression tends to be positively related to multiple infiltrating immune cells, while negatively related to CD56 dim nature killer cell in glioma. Some important immune checkpoints, like CTLA-4, PD-L1, EGF, CD96, and CD226, were all positively related with DDX60 (all Pearson correlation R > 0.26). The expression and correlation between DDX60, EGF, and PD-L1 were confirmed by western blot in clinical samples (n = 14, P < 0.0001) and GBM cells. These results indicated that DDX60 might have important clinical significance in glioma and could serve as a potential immune therapeutic target. Frontiers Media S.A. 2021-06-10 /pmc/articles/PMC8222729/ /pubmed/34178649 http://dx.doi.org/10.3389/fonc.2021.665360 Text en Copyright © 2021 Zhang, Fu, Zhang, Zhang, Du, Zhang, Hua and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Jingwen Fu, Minjie Zhang, Mengli Zhang, Jinsen Du, Zunguo Zhang, Hongyi Hua, Wei Mao, Ying DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title |
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title_full |
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title_fullStr |
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title_full_unstemmed |
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title_short |
DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker |
title_sort | ddx60 is associated with glioma malignancy and serves as a potential immunotherapy biomarker |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222729/ https://www.ncbi.nlm.nih.gov/pubmed/34178649 http://dx.doi.org/10.3389/fonc.2021.665360 |
work_keys_str_mv | AT zhangjingwen ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT fuminjie ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT zhangmengli ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT zhangjinsen ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT duzunguo ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT zhanghongyi ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT huawei ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker AT maoying ddx60isassociatedwithgliomamalignancyandservesasapotentialimmunotherapybiomarker |